Bidirectional effect of met-enkephalin on macrophage effector functions.
Met-enkephalin (ME) exerts a bimodal effect on functional activities of rat peritoneal macrophages (PM); in a range of low concentration (10(-9)-10(-7)M) antibody dependent cellular cytotoxicity (ADCC) was markedly stimulated with a simultaneous decrease of Fc gamma receptor (Fc gamma R) medicated phagocytosis while the opposite was observed at 10(-6)-10(-5)M concentrations. Studying the possible underlying mechanism(s) the followings were recorded: (1) ME in all applied concentrations induced an early Na+ influx which was followed by a Ca2+ efflux in the range of low concentrations. In the range of high concentrations Na+ influx was accompanied by a Ca2+ influx. (2) ME at 10(-8) M concentration induced a rise in cGMP level with a plateau in the 60-120th min of incubation. This effect was prevented by 10(-5) M of naloxone. At 10(-6) M concentration a transient rise of cAMP level was recorded which was not affected by naloxone. (3) Verapamil in 10(-6) M abolished both the Ca2+ influx and the rise in cAMP level induced by 10(-6)-10(-5) M ME but not the rise in cGMP level induced by lower ME concentrations. (4) cAMP elevation by high ME concentrations was abolished by enkephalinase inhibitory puromycin. (5) PM-enkephalinase as assessed by the cleavage of fluorogenic substrate L-alanine beta naphthylamide (ABNA), was inhibited by 10(-6)-10(-5) M of ME. This inhibition was abolished by verapamil, but not affected by naloxone. In the range of low concentrations ME appears to act on specific delta opioid receptors and its action is positively coupled to guanylate cyclase. In relatively higher concentrations ME-action is not mediated by specific delta opioid receptors and it appears to involve Ca2+ influx, adenylate cyclase activation as well as the processing of hormone by PM-enkephalinase.
Fóris
G
G
Medgyesi
G A
GA
Hauck
M
M
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D010450:Endopeptidases / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000494:pharmacology*; D006162:Guanylate Cyclase / Q000378:metabolism; D007473:Ion Channels / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D015260:Neprilysin; D010587:Phagocytosis; D051381:Rats; D011919:Rats, Inbred Strains; D011961:Receptors, Fc / Q000276:immunology; D017452:Receptors, IgG; D012964:Sodium / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology
D007473:Ion Channels; D011961:Receptors, Fc; D017452:Receptors, IgG; D009270:Naloxone; D004744:Enkephalin, Methionine; D012964:Sodium; D014700:Verapamil; D000242:Cyclic AMP; D010450:Endopeptidases; D015260:Neprilysin; D000262:Adenylyl Cyclases; D006162:Guanylate Cyclase; D006152:Cyclic GMP; D002118:Calcium